Her-Vaxx vs Herceptin vs Cisplatin, page-16

The market has obviously seen the results as underwhelming.

A few points to note about the negative market reaction:

- Most shareholders wouldn't even be able to differentiate between an average result, a good result, or a great result, of a specific clinical trial.

- Most shareholders don't have a deeper understanding of clinical trials, and how they're run.

- I suspect a fair few were perhaps even expecting results that indicated we had cured cancer.

Let's not forget one very important factor. These patients were on their last legs. So to show anything which indicated a response (that was both safe and well tolerated), let alone a 30% reduction in tumor size (for five patients), sounds amazing to me.

Another important thing to note is that of the 14 patients, not all received the 50 microgram dosage. For all we know (and hypothetically speaking), if all 14 patients received the maximum dose of 50 micrograms (as will happen in Phase II), the results could have been 10 of 14 patients showing >30% decrease in their tumor reduction. That is why you can't read too much into Phase I results, as it's sole purpose (in the case of cancer drugs) is to test safety, dosage, and whether the treatment shrank the tumor. NOT how many people in total showed full response or partial response, as not all patients received the optimal dosage of 50 micrograms (in our case).